Fluorescence Lifetime-Based FRET Biosensors for Monitoring N Terminal Domain-Dependent Interactions of TDP-43 in Living Cells: A Novel Approach for ALS and FTD Drug Discovery
ACS Chemical Neuroscience · 2025
DOI: 10.1021/acschemneuro.5c00266 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Noah Nathan Kochen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States. Hauptthemen laut MEDLINE: Biosensing Techniques, Fluorescence Resonance Energy Transfer, DNA-Binding Proteins, Frontotemporal Dementia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pathological aggregates of TDP-43 are implicated in Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. While therapeutic efforts have traditionally focused on mitigating end-stage TDP-43 aggregation, recent evidence highlights an upstream and potentially targetable event: the loss of functional nuclear TDP-43 multimers due to disrupted N-terminal domain (NTD) interactions. To address this, we developed fluorescence lifetime (FLT)-based FRET biosensors to monitor TDP-43 multimerization in living cells that couple a full-length TDP-43 FLT-FRET biosensor screen with an NTD-deletion counter screen, forming the foundation of a novel high-throughput screening (HTS) platform. Screening the 2682 compound FDA-approved Selleck library, we identified the small molecule ketoconazole, which stabilizes functional nuclear TDP-43 multimers in an NTD-dependent manner with low micromolar potency. Ketoconazole rescues TDP-43 mislocalization and aggregation, restores SREBP2 mRNA levels under TDP-43 overexpression, improves neuronal health, and partially restores motor function in a TDP-43 C. elegans model. These findings establish both the biosensors and the HTS platform as innovative tools for TDP-43 drug discovery and support an exciting translational approach for targeting TDP-43 proteinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States.
- Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota 55455, United States.
ORCID-Profile: Noah Nathan Kochen, Marguerite Murray, Nagamani Vunnam, Anthony R Braun, Jonathan N Sachs
Zitieren
APA
Nathan Kochen, N., Murray, M., Zafari, S., Vunnam, N., Liao, E. E., Chen, L., Braun, A. R., & Sachs, J. N. (2025). Fluorescence Lifetime-Based FRET Biosensors for Monitoring N Terminal Domain-Dependent Interactions of TDP-43 in Living Cells: A Novel Approach for ALS and FTD Drug Discovery. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00266
Vancouver
Nathan Kochen N, Murray M, Zafari S, Vunnam N, Liao EE, Chen L, et al. Fluorescence Lifetime-Based FRET Biosensors for Monitoring N Terminal Domain-Dependent Interactions of TDP-43 in Living Cells: A Novel Approach for ALS and FTD Drug Discovery. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00266
BibTeX
@article{NathanKochen2025,
author = {Nathan Kochen, Noah and Murray, Marguerite and Zafari, Sophia and Vunnam, Nagamani and Liao, Elly E and Chen, Lihsia and Braun, Anthony R and Sachs, Jonathan N},
title = {Fluorescence Lifetime-Based FRET Biosensors for Monitoring N Terminal Domain-Dependent Interactions of TDP-43 in Living Cells: A Novel Approach for ALS and FTD Drug Discovery},
journal = {ACS Chemical Neuroscience},
year = {2025},
doi = {10.1021/acschemneuro.5c00266}
}
EUVIMED